Moleculin Biotech, Inc. · NASDAQ:MBRX
Moleculin Biotech — Investor Presentation (March 2024)
22 slides from Moleculin Biotech's investor presentation, Mar 25, 2024
Slide 1: Moleculin
-:SMOLECULIN We is
Slide 2: Disclaimer
Disclaimer Allstatements contained herein other than statements of historical fac, including statements regarding our future results of operations ad financial position, ‘our business strategy and plans, and our objectives for future operations, are forward-looking statements. The words “believe.” “
Slide 3: Core Management Belief...
Core Management Belief... hracyclines represent the most important t line treatments for AML and Advanced STS. Annamycin allows, for the first time ever, a clear majority of patients to benefit from these treatments.
Slide 4: Management Team
Management Team Board of Directors
Slide 5: We Are Advancing a growing pipeline of clinical programs
We Are Advancing ‘a growing pipeline ot clinical programs to treat highly resistant / Pipeline Expansion cancers and viruses. Opportunities for additional high-value oncology indications {© Annamycin Lead program, next-generation non-cardiotoxic anthracycline with notable signs of efficacy in AML an
Slide 6: Priority Drug Candidate Development Pipeline
Priority Drug Candidate Development Pipeline SV i ‘rms 2 ire ‘Annamycin: Potential for additional indications: cs Tine pee rtrgtinnmas Reale atone
Slide 7: The Annamycin Opportunity in AML
The Annamycin Opportunity in AML = Annamycin in combination with Cytarabine (AnnAraC) has potential to fill unmet need in AML; 60% Rc (50%CR) in 2nd line patients reported in latest Phase 18/2 study AnnAraC expected to more than double 2nd line AML CRs All 82 Annamycin subjects (in multiple studies)
Slide 8: Annamycin Attributes
Annamycin Attributes ‘Avoids cross resistance with existing anthracyclines, Ara-Cand . : eee Non-Cardiotoxic precinkcal mode's validated by independent exper (63 . sublets revewesto dee) (Wetime maxfor dex 550 ma/n2) aberrant More potent than aS doxin mes turer mee No vesicant activity (safter to ha
Slide 9: Approved Therapies are Successful for <40% of ~20,000 Annual Newly Diagnosed AML Patients
Approved Therapies are Successful for <40% of the ~20,000 Annual Newly Diagnosed AML Patients Daunorubicin| Venetoclax | Targeted Therapy Regimen 743 Ven-Aza __Gene-Targeted Sub-population FitPatients Unfit Elderly §5%.65% (50%) (60%) Eligible Durable CR% 36% 37% ~21% All AML benefit! 14% 15% 7% Sti
Slide 10: Competitive Landscape — CR/CRi Approval Rates
Competitive Landscape — CR/CRi Approval Rates’ 70.0% Gilteritinid _Esasidenib? _tvosidenib2 Olutasidenib2 Gemtuzumab4 AnnAraC3 — AnnAraC? (Xospata) (ihifa)—(Titsovo) (Reza) (Mylotarg) (AnnatéraC) (AnnatraC) (Furs) (10H2)-—— (DH) (IOHX)— (CD33) fat 7line (2 Line ment mca cre Low Bar for Approval Pewo
Slide 11: >50% of AML Patients Are Ineligible for Approved Targeted Therapies
>50% of AML Patients Are Ineligible for Approved Targeted Therapies AnnAraC Treats All-Comers in 2"4 Line rouecuum
Slide 12: AnnAraC Should Increase 2nd Line AML CRs 2-Fold or More
AnnAraC Should Increase 2™ Line (2L) AML CRs 2-Fold or More 60.0% 1 50.0% : 50.0% 13% of 2LAML patients expected to ' ' achieve CR 1 ' 40.0% 1 i , Ne ‘ 30.0% 1 i 1 t 20.0% : 1 t 10.0% oa | 23% 1.7% 24% \] 13x! A 1 0.0% a = = ma i ' 1 Gilteritinib Esasidenib _IvosidenibOlutasidenib Gemtuzumab, AnnAra
Slide 13: The Full Annamycin Opportunity
The Full Annamycin Opportunity Potential for Significant Upside — 41k TNBCLUng 13,500 STS Lung Metastases 20,000 ‘Acute Myeloid Leukemia Initial Annamycin Target Indications PotentiatAnamycin Exparsen indications TOTALINCIDENCE ~33.5K TOTAL INCIDENCE ~A78K 20k Acute Myetoi Leukerria 13K sts —“ Ostec
Slide 14: Advancing Annamycin in AML
Advancing Annamycin in AML Phase 1: MB-104 Phase 1/2: MB-105 MONOTHERAPY + N=6 + N=20 + 17%CRi at suboptimal dosing) + Median lines of prior therapy = 4 * Dosing limited by FDA Lifetime + Median age of 240 mg/m? (RPD2) Anthracycline cohort = 65 years Dose (LTMAD) + 60% CR/CRI in 240mg/m? Cohort (N=
Slide 15: MB-106 Proving Potential Efficacy in AML
MB-106 Proving Potential Efficacy in AML Subjects Evaluable To Date Subjects Evaluable No! Dosed Per Protocol ‘Median Prior Therapie: Median Age - Years (Range] Complete Response (CR] Rat Complete Responsd Composite (CRe) Rat Partial Responses (PRs} Rc Relapsed To Date BMT To Dati Durability of CA ‘
Slide 16: Significant Patient Experiences in MB-106 Annamycin + Ara-C
Significant Patient Experiences in MB-106 Annamycin + Ara-C 2Armstudy (7 mos) veryea(17) cR ~12mos (climbing) Feb2023/3 Ven/Ava (3) cR ~8mos (Successful BMT 4 mos after singlecourse) Jun 2023/1 78-Relapsed 64-Refractory 70-Relapsed kladeybine/Cyt arabine (2) ytarabine (11) cr Amos (relapsed) ‘Sep 20
Slide 17: Annamycin Has Demonstrated Substantially Greater Cardiac Safety
Annamycin Has Demonstrated Substantially Greater Cardiac Safety Compared to Approved Anthracyclines Current Anthracyclines Annamycin Zan a | Cardiotoxicity jeart Failure
Slide 18: Annamycin Demonstrates Efficacy in STS Lung Metastases (MB-107)
Annamycin Demonstrates Efficacy in STS Lung Metastases (MB-107) Demonstrated Stable Disease After Demonstrated Improvement with Dose < 330 mg/m? ‘Two Treatment Cycles and Fewer Prior Therapies. All Subjects in Phase 18, I Developing Dewesng Deep Deseo Overall survival (05); Phase 2 subjectsinterim a
Slide 19: Global Network
Global Network Alltechnology licensed from MD Anderson Cancer Center (MDACC) & Supports continuing preclinical research on our technology at MDACC close to $1M per year Supports preclinical research at UTMB Past & current externally funded trials MD Anderson Cancer Center; Emory University, Aflac Ca
Slide 20: Cash to Fund Operations into the Fourth Quarter of 2024
Cash to Fund Operations into the Fourth Quarter of 20241 Nasdaq: MBRX O ~$23.6M Cash Balance? bear ~$22.5M Market Cap? % ~2.2M Shares Outstanding* \ ~55K 3-Month Avg. Weekly Volume?
Slide 21: Upcoming Milestones
Upcoming Milestones Ee Complete MB-106 clinical trial 1H 2024 Present topline data from MB-106 clinical trial 1H 2024 ANNAMYCIN x4 of Phase 2(EOP2) Meeting 1H 2024 | AML Report outcome of MB-106 End of Phase 2 Meeting 2H 2024 Initiate pivotal program 2H 2024 into 1H 2025 7 ee umm | STSLUNG —_identfy
Slide 22: Core Management Belief...
Core Management Belief... Anthracyclines are among the most in treatments for AMLand Advanced STS. Annamycin allows, for the first time ever, a clear majority of patients to benefit from these treatments.
Moleculin Biotech — Investor Presentation (March 2024) on 6ix